Bacterial and mycobacterial infections

Therapy of Skin Diseases: A Worldwide Perspective on Therapeutic Approaches and Their Molecular Basis

Volumn , Issue , 2010, Pages 129-148

  French, Nicole ^a   Modlin, Robert L ^b  

^a UCLA School of Medicine ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861313432     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-78814-0_14     Document Type: Chapter

References (79)

1. Stevens DL et al (2005) Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41(10):1373-1406 (Pubitemid 41581713)
2. Lejbkowicz F, Samet L, Belavsky L et al (2005) Impetigo in soldiers after hand-to-hand combat training. Mil Med 170(11):972-974 (Pubitemid 41627890)
3. Kuniyuki S, Nakano K, Maekawa N et al (2005) Topical antibiotic treatment of impetigo with tetracycline. J Dermatol 32(10):788-792 (Pubitemid 41703754)
4. Amagai M, Matsuyoshi N, Wang ZH et al (2000) Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 6(11):1275-1277
5. Koning S, Mohammedamin RS, van der Wouden JC et al (2006) Impetigo: incidence and treatment in Dutch general practice in 1987 and 2001-results from two national surveys. Br J Dermatol 154(2):239-243 (Pubitemid 43382692)
6. Ratnam S, Hogan K, March SB et al (1986) Whirlpool-associated folliculitis caused by Pseudomonas aeruginosa: report of an outbreak and review. J Clin Microbiol 23(3):655-659 (Pubitemid 16137783)
7. Moran GJ, Krishnadasan A, Gorwitz RJ et al (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355(7):666-674
8. Raz R, Miron D, Colodner R et al (1996) A 1 year trial of nasal mupirocin ointment in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med 156:1109
9. Klempner MS, Styrt B (1988) Prevention of recurrent staph-ylococcal skin infections with low-dose oral clindamycin therapy. JAMA 260:2682-2685 (Pubitemid 18261979)
10. Eriksson B, Jorup-Ronstrom C, Karkkonen K et al (1996) Erysipelas: clinical and bacteriologic spectrum and serologi-cal aspects. Clin Infect Dis 23(5):1091-1098 (Pubitemid 26367499)
11. Dupuy A, Benchikhi H, Roujeau JC et al (1999) Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 318(7198):1591-1594 (Pubitemid 29267772)
12. Swartz MN (2004) Clinical practice: cellulitis. N Engl J Med 350:904-912
13. Bernard P, Plantin P, Roger H et al (1992) Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol 127:155-159
14. Bergkvist PI, Sjobeck K (1997) Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis 29(4):377-382
15. Baddour LM, Bisno AL (1984) Recurrent cellulitis after coronary bypass surgery. Association with superficial fungal infection in saphenous venectomy limbs. JAMA 251(8):1049-1052 (Pubitemid 14190698)
16. Perl B, Gottehrer NP, Raveh D et al (1999) Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 29:1483-1488 (Pubitemid 30022745)
17. Wang JH, Liu YC, Cheng DL et al (1997) Role of benza-thine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis 25(3): 685-689
18. Lazzarini et al (2005) Erysipelas and cellulitis: clinical and microbiological spectrum in an Italian tertiary care hospital. J Infect 51(5):383-389 (Pubitemid 43008962)
19. Brook I, Frazier EH (1995) Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol 33: 2382
20. Wong CH, Chang HC, Pasupathy S et al (2003) Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 85-A:1454
21. Kaul R, McGeer A, Low DE et al (1997) Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiological analysis of seventy-seven cases. Ontario Group A Streptococcal study. Am J Med 103:118-124
22. Stevens DL (1995) Streptococcal toxic shock syndrome: spectrum of disease, pathogenesis and new concepts in treatment. Emerg Infect Dis 1:96
23. Stevens DL, Gibbons AE, Bergstrom R et al (1988) The Eagle effect revisited: efficacy of clindamycin, erythromy-cin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 158:23
24. Zimbelman J, Palmer A, Todd J (1999) Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 18:1096
25. Norrby-Teglund A et al (2005) Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspe-cific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 37(3):166-172 (Pubitemid 40372838)
26. O'Brien KL, Beall B, Barrett NL et al (2002) Epidemiology of invasive group A streptococcus disease in the United States, 1995-1999. Clin Infect Dis 35:268-276 (Pubitemid 34800274)
27. Dillon HC (1980) Topical and systemic therapy for pyoder-mas. J Dermatol 19:443-451
28. Johnston GA (2004) Treatment of bullous impetigo and the staphylococcal scalded skin syndrome in infants. Expert Rev Anti Infect Ther 2(3):439-446 (Pubitemid 38745102)
29. Patel GK, Finlay AY (2003) Staphylococcal scalded skin syndrome: diagnosis and management. Am J Clin Dermatol 4(3):165-175 (Pubitemid 36390473)
30. Mockenhaupt M, Idzko M, Grosber M et al (2005) Epidemiology of staphylococcal scalded skin syndrome in Germany. J Invest Dermatol 124(4):700-703 (Pubitemid 40489495)
31. Petosa C, Collier RJ, Klimpel KR et al (1997) Crystal structure of the anthrax toxin protective antigen. Nature 385(6619):833-838 (Pubitemid 27106075)
32. Bradley KA, Mogridge J, Mourez M et al (2001) Identification of the cellular receptor for anthrax toxin. Nature 414(6860): 225-229 (Pubitemid 33051239)
33. CDC (2001) From the Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy. JAMA 286(18):2226-2232
34. Wright GG, Green TW, Kanode RG (1954) Studies on immunity in anthrax. Immunizing activity of alum-precipitated protective antigen. J Immunol 73:387-391
35. Turnbull P et al (1986) Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 52:356-363 (Pubitemid 16117786)
36. Advisory Committee on Immunization Practices (2000) Use of anthrax vaccine in the United States. MMWR Recomm Rep 49(RR-15):1-20
37. Scorpio et al (2006) Biological weapons: Anthrax vaccines: pasteur to the present. Cell Mol Life Sci 63(19-20): 2237-2248 (Pubitemid 44653037)
38. Turnbull P (1998) Guidelines for the surveillance and control of anthrax in humans and animals, 3rd edn. World Health Organization WHO/EMC/ZDI/98.6
39. Glassman HN (1958) World incidence of anthrax in man. Public Health Rep 73:22-24
40. Pile JC, Malone JD, Eitzen EM et al (1998) Anthrax as a potential biological warfare agent. Arch Intern Med 158: 429-434 (Pubitemid 128681603)
41. Yamamura M et al (1991) Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254:277-279 (Pubitemid 21917340)
42. Yamamura M et al (1992) Cytokine patterns of immunologi-cally mediated tissue damage. J Immunol 149:1470-1475
43. World Health Organization (1982) Chemotherapy of leprosy for control programs: technical report series 675. World Health Organization, Geneva
44. Single-lesion Multicentre Trial Group (1997) Efficacy of single dose multidrug therapy for the treatment of singlelesion paucibacillary leprosy. Indian J Lepr 69(2):121-129
45. Narang T, Kaur I, Kumar B et al (2005) Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy. Int J Lepr Other Mycobact Dis 73(2):105-114
46. Anon (2006) Global leprosy situation, 2006. Wkly Epidemiol Rec 81(32):309-316
47. World Health Organization (2002) Report on third meeting of the WHO technical advisory group on elimination of leprosy. World Health Organization, Geneva, WHO/CDS/CPE/CEE/2002.29
48. Lockwood DN (1997) Rifampicin, ofloxacin and minocy-cline (ROM) for single lesions in leprosy. What is the evidence? Lepr Rev 6:299-300 (Pubitemid 28058644)
49. Hopewell P, Pai M, Maher D et al (2006) International standards for tuberculosis care. Lancet Infect Dis 6(11): 710-725 (Pubitemid 44740086)
50. Nahid P, Madhukar P, Hopewell PC (2006) Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc 3(1):103-110
51. Burman WJ, Gallicano K, Peloquin C (2001) Comparative pharmokinetics and pharmodynamics of the rifamycin anti-bacterials. Clin Phamacokinet 40:327-341 (Pubitemid 32565595)
52. Weiner M, Bock N, Peloquin CA et al (2004) Pharmokinetics of rifapentine at 600, 900 and 1, 200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 169: 1191-1197 (Pubitemid 38680395)
53. Sehgal VN, Srivastava G, Khurana VK et al (1987) An appraisal of epidemiologic, clinical, bacteriologic, histo-pathologic, and immunologic parameters in cutaneous tuberculosis. Int J Dermatol 26(8):521-526
54. Ho CK, Ho MH, Chong LY (2006) Cutaneous tuberculosis in Hong Kong: an update. Hong Kong Med J 12(4): 272-277 (Pubitemid 44285140)
55. Crofton J, Chaulet P, Mahet D (1997) Guidelines for the management of drug-resistant TB. Global Tuberculosis Programme, WHO, Geneva, Switzerland
56. Umapathy KC, Begum R, Ravichandran G et al (2006) Comprehensive findings on clinical, bacteriological, histo-pathological and therapeutic aspects of cutaneous tuberculosis. Trop Med Int Health 2006(10):1521-1528 (Pubitemid 44450557)
57. Chomel BB (2000) Cat-scratch disease. Rev Sci Technol 19:136-150
58. Bass JW, Vincent JM, Person DA (1997) The expanding spectrum of Bartonella infections II Cat-scratch disease. Pediatr Infect Dis J 16:163-179 (Pubitemid 27078785)
59. Bass JW et al (1998) Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 17(6):447-452 (Pubitemid 28287606)
60. Rolain JM, Brouqui P, Koehler JE et al (2004) Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 48(6): 1921-1933 (Pubitemid 38691578)
61. Reed JB, Scales DK, Wong MT et al (1998) Bartonella henselae neuroretinitis in cat-scratch disease. Diagnosis, management, and sequelae. Ophthalmology 105:459-466 (Pubitemid 28125099)
62. Marra CM (1995) Neurologic complications of Bartonella henselae infection. Curr Opin Neurol 8(3):164-169
63. Perkocha LA et al (1990) Clinical and pathological features of bacillary peliosis hepatis in association with human immunodeficiency virus infection. N Engl J Med 323(23): 1581-1586
64. Spach DH et al (1993) Endocarditis caused by Rochalimaea quintana in a patient infected with human immunodeficiency virus. J Clin Microbiol 31(3):692-694 (Pubitemid 23059891)
65. Jameson P, Greene C, Regnery R et al (1995) Prevalence of Bartonella henselae antibodies in pet cats throughout regions of North America. J Infect Dis 172:1145-1149
66. Jackson LA, Perkins BA, Wenger JD (1993) Cat scratch disease in the United States: an analysis of three national databases. Am J Public Health 83:1707-1711 (Pubitemid 24009499)
67. Hopla CE (1974) The ecology of tularemia. Adv Vet Sci Comp Med 18:25-53
68. Tarnvik A (1989) Nature of protective immunity to Francisella tularensis. Rev Infect Dis 11:440-451
69. Sjostedt A (2006) Intracellular survival mechansisms of Francisella tularensis, a stealth pathogen. Microbes Infect 8(2):561-567 (Pubitemid 43214620)
70. Sjostedt A, Eriksson U, Berglund L et al (1997) Detection of Francisella tularensis in ulcers of patients with tularemia by PCR. J Clin Microbiol 35:1045-1048 (Pubitemid 27175222)
71. Sandstrom G (1994) The tularemia vaccine. J Chem Tech Biotech 59:315-320
72. Enderlin G, Morales L, Jacobs RF et al (1994) Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 19(1):42-47 (Pubitemid 24227033)
73. Oyston P, Quarry J (2005) Tularemia vaccine: past, present, and future. Antonie van Leeuwenhoek 87:277-281 (Pubitemid 41349036)
74. Tarnvik A, Berglund L (2003) Tularemia. Eur Respir J 21: 361-373
75. Hayes E, Dennis D, Feldman K (2002) Tularemia: United States, 1990-2000. MMWR Morb Mortal Wkly Rep 51: 182-184
76. Pollitzer R (1967) History and incidence of tularemia in the Soviet Union: a review. The Institute of Contemporary Russian studies. Fordham University, Bronx, NY
77. Tarnvik A, Sandstrom G, Sjostedt A (1996) Epidemiological analysis of tularemia in Sweden 1931-1993. FEMS Immunol Med Microbio 13:201-204 (Pubitemid 26133331)
78. Aranda EA (2001) Treatment of tularemia with levofloxacin. Clin Microbio Infect 7:167-168
79. Limaye AP, Hooper CJ (2003) Treatment of tularemia with fluoroquinolones: two cases and review. Eur Respir J 21: 361-373